Molecular Partners First Quarter 2025 Earnings: CHF0.45 loss per share (vs CHF0.34 loss in 1Q 2024)

Molecular Partners (VTX:MOLN) First Quarter 2025 Results

Key Financial Results

• Net loss: CHF16.8m (loss widened by 48% from 1Q 2024).
• CHF0.45 loss per share (further deteriorated from CHF0.34 loss in 1Q 2024).

We've discovered 4 warning signs about Molecular Partners. View them for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Molecular Partners Earnings Insights

Looking ahead, revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Europe.

Performance of the market in Switzerland.

The company's shares are down 5.2% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 4 warning signs for Molecular Partners (1 makes us a bit uncomfortable) you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.